Virus News and Research

Latest Virus News and Research

Researchers to study effect of reovirus on cancer cells

A common virus that can cause coughing and mild diarrhea appears to have a major redemptive quality: the ability to kill cancer. Harnessing that power, researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center, are conducting a clinical trial to see if the virus can target and kill certain tumor types.

21 Oct 2010

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.

21 Oct 2010

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

Abbott today announced financial results for the third quarter ended Sept. 30, 2010.

20 Oct 2010

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Los Alamos National Laboratory researcher Bette Korber is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The vaccine represents a novel strategy for fighting the virus that causes AIDS by attempting to address one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity.

20 Oct 2010

Cubist announces pricing of 2.50% Convertible Senior Notes due 2017

Cubist Pharmaceuticals, Inc. today announced the successful pricing of $400 million aggregate principal amount of its 2.50% Convertible Senior Notes due 2017. Cubist has granted the underwriters an option to purchase up to an additional $50 million aggregate principal amount of the notes.

20 Oct 2010

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

20 Oct 2010

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).

20 Oct 2010

Pharmacy graduate awarded national recognition for pioneering research in genetics

A young pharmacy graduate has been awarded national recognition for her pioneering research in the field of genetics which has the potential to treat diseases such as cancer and Parkinson's.

19 Oct 2010

Health care reform will lead more people to seek cancer prevention and risk-reduction services

More people will likely seek cancer prevention and risk-reduction services as a result of health care reform, say experts at The University of Texas MD Anderson Cancer Center.

19 Oct 2010

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).

19 Oct 2010

New research coalition to design first human trial of mosaic HIV vaccine candidate

Duke University Medical Center vaccine experts have assembled an international team of investigators to design and implement the first human trial of a mosaic HIV vaccine candidate, a novel strategy that attempts to counter one of the most daunting challenges in HIV vaccine design: the virus's extensive genetic diversity

19 Oct 2010

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

Micronics, Inc., a development-stage company, today announced that the Department of Defense has awarded the company an Applied Research and Technology Development Award under the U.S. Army Medical Research and Materiel Command's Polytrauma and Blast Injury project for advancement of its PanNAT system for point-of-care molecular diagnosis of infectious pathogens.

19 Oct 2010

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)).

19 Oct 2010

Egg allergy is no reason to avoid 2010-2011 flu vaccination

Having an egg allergy is not a reason to avoid getting the 2010-2011 flu vaccination.

19 Oct 2010

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Findings from the PRECiSE 3 (P3) open label extension study for Cimzia, demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20. Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

19 Oct 2010

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) of BARACLUDE for the treatment of chronic hepatitis B (CHB) in adult patients with decompensated liver disease.

18 Oct 2010

GeoVax Labs contributes article for HIV vaccine

Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN).

18 Oct 2010

Virus News and Research

Latest Virus News and Research

Researchers to study effect of reovirus on cancer cells

IRB approves CEL-SCI’s Multikine Phase III clinical trial for head and neck cancer

Abbott third quarter worldwide sales increase 11.8% to $8.7 billion

LANL's researcher to implement first human trial of mosaic HIV vaccine candidate

Cubist announces pricing of 2.50% Convertible Senior Notes due 2017

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Pharmacy graduate awarded national recognition for pioneering research in genetics

Health care reform will lead more people to seek cancer prevention and risk-reduction services

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

New research coalition to design first human trial of mosaic HIV vaccine candidate

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

Egg allergy is no reason to avoid 2010-2011 flu vaccination

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

GeoVax Labs contributes article for HIV vaccine

NanoViricides' President delivers speech at ASNM Second Annual Conference

Major advance in treatment of brain disorders with external genes

ACG meeting to exhibit Cimzia data for Crohn's disease treatment

A new way of characterising biomolecules eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in